United States — Food and Drug Administration & Goldman Sachs
8 shared events · Importance 4 · Last updated Jun 08, 2026
Live sentiment trends, interaction importance charts, and action volume tracking available on the
NewsDesk Dashboard
Business
United States — Food and Drug Administration: The United States — Food and Drug Administration granted Breakthrough Therapy designation to Oculis's Privosegtor, highlighting its potential.
Goldman Sachs: Goldman Sachs is hosting the Global Healthcare Conference, providing a platform for Oculis to present its updates.
Jun 08, 2026 · 6 articles
Business
United States — Food and Drug Administration: The United States — Food and Drug Administration is mentioned as the regulatory body whose approval is sought for Coya Therapeutics' therapies, highlighting the importance of regulatory milestones for the company's future.
Goldman Sachs: Goldman Sachs is hosting the 47th Annual Global Healthcare Conference 2026, providing a platform for companies like Coya Therapeutics to engage with the investment community.
Jun 02, 2026 · 7 articles
Business
United States — Food and Drug Administration: The United States — Food and Drug Administration is currently reviewing the New Drug Application for rusfertide.
Goldman Sachs: Goldman Sachs is hosting one of the investment bank conferences where AnBogen Therapeutics will present.
May 28, 2026 · 6 articles
Business
United States — Food and Drug Administration: The United States — Food and Drug Administration approved NUZOLVENCE, one of Innoviva's products.
Goldman Sachs: Goldman Sachs is hosting the 47th Annual Global Healthcare Conference, where Innoviva will participate in a fireside chat.
Jun 01, 2026 · 6 articles
NEWSDESK
Explore this relationship live
Track how United States — Food and Drug Administration and Goldman Sachs interact across events, view sentiment trends, and discover connected entities.
Open Dashboard